Primary |
Product Used For Unknown Indication |
66.2% |
Neuralgia |
6.0% |
Pain |
4.5% |
Neuropathy Peripheral |
4.0% |
Epilepsy |
3.0% |
Back Pain |
2.0% |
Diabetic Neuropathy |
1.5% |
Hiv Infection |
1.5% |
Drug Use For Unknown Indication |
1.0% |
Arthritis |
1.0% |
Diabetic Nephropathy |
1.0% |
Essential Tremor |
1.0% |
Fibromyalgia |
1.0% |
Insomnia |
1.0% |
Nerve Block |
1.0% |
Pain In Extremity |
1.0% |
Polyneuropathy |
1.0% |
Prostatomegaly |
1.0% |
Trigeminal Neuralgia |
1.0% |
Back Pain |
0.5% |
|
Toxicity To Various Agents |
24.7% |
Exposure Via Ingestion |
15.3% |
Completed Suicide |
11.8% |
Overdose |
5.9% |
Wrong Drug Administered |
4.7% |
Exposure During Pregnancy |
3.5% |
Off Label Use |
3.5% |
Death |
2.4% |
Drug-induced Liver Injury |
2.4% |
Erythema |
2.4% |
Loss Of Consciousness |
2.4% |
Mood Swings |
2.4% |
Neuropathy Peripheral |
2.4% |
Paraesthesia |
2.4% |
Renal Impairment |
2.4% |
Respiratory Arrest |
2.4% |
Suicidal Ideation |
2.4% |
Therapeutic Response Unexpected |
2.4% |
Ventricular Tachycardia |
2.4% |
Vomiting |
2.4% |
|
Secondary |
Product Used For Unknown Indication |
67.7% |
Completed Suicide |
6.9% |
Temporal Lobe Epilepsy |
3.7% |
Central Pain Syndrome |
3.2% |
Depression |
2.6% |
Intentional Overdose |
2.6% |
Status Epilepticus |
2.1% |
Plasma Cell Myeloma |
1.6% |
Porphyria Acute |
1.6% |
Seizures |
1.6% |
Neuralgia |
1.1% |
Psychotic Disorder |
1.1% |
Back Disorder |
0.5% |
Back Pain |
0.5% |
Drug Use For Unknown Indication |
0.5% |
Gait Disturbance |
0.5% |
Gastritis |
0.5% |
Hypertension |
0.5% |
Insomnia |
0.5% |
Mood Disorder Nos |
0.5% |
|
Toxicity To Various Agents |
36.1% |
Respiratory Arrest |
11.1% |
Renal Impairment |
5.6% |
Completed Suicide |
2.8% |
Diarrhoea |
2.8% |
Dry Throat |
2.8% |
Epilepsy |
2.8% |
Exposure During Pregnancy |
2.8% |
Femoral Neck Fracture |
2.8% |
Hallucination, Auditory |
2.8% |
Hypersensitivity |
2.8% |
Infarction |
2.8% |
Mood Swings |
2.8% |
Myoclonus |
2.8% |
Oxygen Saturation Decreased |
2.8% |
Platelet Count Decreased |
2.8% |
Pneumonia |
2.8% |
Poisoning |
2.8% |
Pulmonary Embolism |
2.8% |
Rash |
2.8% |
|
Concomitant |
Multiple Sclerosis |
26.4% |
Plasma Cell Myeloma |
21.5% |
Product Used For Unknown Indication |
9.6% |
Depression |
5.1% |
Gait Disturbance |
4.5% |
Chronic Myeloid Leukaemia |
3.1% |
Hepatitis C |
3.1% |
Prophylaxis |
2.7% |
Prostate Cancer Metastatic |
2.7% |
Type 2 Diabetes Mellitus |
2.7% |
Relapsing-remitting Multiple Sclerosis |
2.5% |
Drug Use For Unknown Indication |
2.2% |
Immunodeficiency Common Variable |
2.2% |
Hypertension |
2.0% |
Myelodysplastic Syndrome |
2.0% |
Osteoporosis |
1.8% |
Systemic Lupus Erythematosus |
1.8% |
B-cell Lymphoma |
1.6% |
Chronic Lymphocytic Leukaemia |
1.3% |
Rheumatoid Arthritis |
1.1% |
|
Vomiting |
11.5% |
Pneumonia |
8.5% |
Nausea |
6.7% |
Vision Blurred |
6.7% |
White Blood Cell Count Decreased |
6.7% |
Visual Impairment |
5.5% |
Pain In Extremity |
4.8% |
Rash |
4.8% |
Tremor |
4.8% |
Urinary Tract Infection |
4.8% |
Neuropathy Peripheral |
4.2% |
Pain |
4.2% |
Somnolence |
4.2% |
Paraesthesia |
3.6% |
Weight Increased |
3.6% |
Fatigue |
3.0% |
Malaise |
3.0% |
Muscle Spasms |
3.0% |
Muscular Weakness |
3.0% |
Rectal Haemorrhage |
3.0% |
|